Pfizer reports FY26 profit of ₹722cr, proposes ₹75 dividend

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorAnanya Iyer|Published at:
Pfizer reports FY26 profit of ₹722cr, proposes ₹75 dividend
Overview

Pfizer Limited has announced its audited financial results for the fiscal year ended March 31, 2026. The company reported a net profit of ₹722.43 crore on total income of ₹2,707.60 crore. The Board of Directors recommended a final dividend of ₹75 per equity share, subject to shareholder approval at the upcoming AGM.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Pfizer Limited announced its audited financial results for the fiscal year ended March 31, 2026. The company reported a net profit of ₹722.43 crore on total income of ₹2,707.60 crore. The Board of Directors recommended a final dividend of ₹75 per equity share, subject to shareholder approval at the upcoming Annual General Meeting.

Total income rose by 10.35% year-on-year to ₹2,707.60 crore in FY2026, compared to ₹2,453.60 crore in FY2025. However, net profit saw a decline of 5.89%, falling to ₹722.43 crore from ₹767.60 crore in the previous year. This profit reduction occurred despite revenue growth, primarily due to rising costs. The company noted an additional provision of ₹7.43 crore for employee benefits in FY2026, citing developments related to India's 'New Labour Codes'.

In other corporate news, Pfizer Limited confirmed it does not meet the 'Large Corporate' criteria set by SEBI as of March 31, 2026, thus avoiding associated obligations. Additionally, M/s. Kishore Bhatia & Associates have been appointed as the company's Cost Auditors for the financial year 2026-27.

The Board's recommendation for a ₹75 per equity share final dividend, if approved by shareholders at the upcoming AGM, will provide a direct financial return to investors. The total payout for this dividend is estimated at ₹343.11 crore.

Investors will be monitoring the impact of the 'New Labour Codes' on employee benefit costs, which could influence future profitability if not managed effectively. The year-on-year profit decline highlights potential margin pressures that the company aims to address.

Pfizer Ltd operates within the competitive Indian pharmaceutical market, alongside major players like Cipla, Sun Pharma, and Dr. Reddy's Laboratories. These companies typically compete on market share through new product launches and expansion, while navigating research and development expenses and regulatory environments.

Investors will await shareholder approval of the ₹75 final dividend at the AGM scheduled for July 28, 2026, with the payout anticipated on or after August 4, 2026. Future financial reports will be crucial for assessing how the company manages adjustments related to the 'New Labour Codes' and any potential reversal in the profit trend.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.